The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

aeriepharma.com

Founded Year

2005

Stage

PIPE | IPO

Total Raised

$71M

Market Cap

0.33B

Stock Price

6.81

About Aerie Pharmaceuticals

Aerie Pharmaceuticals is a privately held, clinical-stage biotechnology company dedicated to the discovery and development of treatments for glaucoma. All technology of the company is based on internal discovery R&D and is protected by a strong IP portfolio. Aerie is developing a diverse portfolio of molecules for ophthalmic use from internal discovery, academia, and industry. In addition, Aerie optimizes delivery of medications to ocular target tissues and enhances patient compliance by developing sustained drug delivery solutions.

Aerie Pharmaceuticals Headquarter Location

550 Hills Drive

Bedminster, New Jersey, 07921,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Aerie Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Aerie Pharmaceuticals is included in 1 Expert Collection, including Diabetes.

D

Diabetes

1,750 items

Aerie Pharmaceuticals Patents

Aerie Pharmaceuticals has filed 71 patents.

The 3 most popular patent topics include:

  • Cannabinoids
  • Diseases of the eye and adnexa
  • G protein coupled receptors
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/22/2020

4/26/2022

Transcription factors, Clusters of differentiation, Cannabinoids, Signal transduction, Piperidines

Grant

Application Date

7/22/2020

Grant Date

4/26/2022

Title

Related Topics

Transcription factors, Clusters of differentiation, Cannabinoids, Signal transduction, Piperidines

Status

Grant

Latest Aerie Pharmaceuticals News

Aerie Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

May 6, 2022

Aerie Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update First Quarter Glaucoma Franchise Net Revenues of $29.8 Million, up 30% over First Quarter 2021 Management Reaffirms 2022 Glaucoma Franchise Guidance of $130 Million to $140 Million First Phase 3 Registrational Trial for AR-15512 On-Track for Enrollment Second Quarter of 2022 DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today reports financial results for the first quarter ended March 31, 2022 and reaffirms the business and pipeline objectives and financial guidance previously reported for 2022. “We continue to execute well on our three strategic pillars to build out Aerie version 2.0. I am pleased to report strong year-over-year revenue growth for our first-in-class glaucoma franchise products, in line with our expectations. We are also excited about the progress we have made with our potential best-in-class dry eye product candidate AR-15512 as we continue to drive efficiencies in our operations,” said Raj Kannan, Chief Executive Officer of Aerie Pharmaceuticals. Mr. Kannan continued, “The addition of Chief Medical Officer Dr. Gary Sternberg and Chief Financial Officer Peter Lang further strengthens our senior leadership team. Driving the growth of our novel commercial franchise, unlocking the potential value in our pipeline and continuing to focus on reducing our net cash burn should position us well for the future.” First Quarter Financial Results and Highlights For the quarter ended March 31, 2022, Aerie reported results compared to the quarter ended March 31, 2021: Total glaucoma franchise net product revenues of $29.8 million, up 30% compared to $23.0 million Net loss of $35.9 million compared to a net loss of $42.0 million Net loss per share (diluted) of $0.76 compared to a net loss per share (diluted) of $0.91 Non-GAAP net loss of $31.3 million compared to non-GAAP net loss of $33.2 million Non-GAAP net loss per share (diluted) of $0.66 compared to non-GAAP net loss per share (diluted) of $0.72 Balance Sheet and Liquidity Highlights Cash, cash equivalents and total investments were $199.2 million as of March 31, 2022 compared to $139.8 million as of December 31, 2021. Cash, cash equivalents and total investments as of March 31, 2022 included $90.0 million of upfront payments received in January, related to our licensing and collaboration agreement with Santen executed in December 2021. During the first quarter of 2022, our net cash provided by operating activities was $61.9 million. Excluding the $90.0 million Santen payment, net cash used in operating activities was $28.1 million. Further, an $8.0 million milestone payment was made in the first quarter of 2022 to the former shareholders of Avizorex Pharma S.L., which was acquired by Aerie in 2019. Outlook for 2022: Business and Pipeline Objectives & Financial Guidance Aerie reaffirms the following business and pipeline objectives and full year guidance previously reported for 2022: Glaucoma franchise net product revenues guidance: $130 million to $140 million, up 16% to 25% versus 2021 Total net cash used: A reduction of approximately 15% in 2022 versus 2021 is expected Phase 3 registrational study initiation for AR-15512 in dry eye: Expected during the second quarter of 2022 Investigational New Drug Application submission for AR-14034 in wet age-related macular degeneration: Expected in the second half of 2022 Conference Call / Webcast Information Aerie management will host a live conference call and webcast at 5:00 p.m. Eastern Time today to discuss Aerie’s financial results and provide a general business update. The live webcast and a replay may be accessed by visiting Aerie’s website at http://investors.aeriepharma.com . Please connect to Aerie’s website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call (888) 734-0328 (U.S.) or (678) 894-3054 (international) to listen to the live conference call. The conference ID number for the live call is 4696464. Please dial in approximately 10 minutes prior to the call. About Aerie Pharmaceuticals, Inc. Aerie is a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies for the treatment of patients with eye diseases and conditions including open-angle glaucoma, dry eye, diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD). Aerie’s first novel product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain and conjunctival hemorrhage. More information about Rhopressa®, including the product label, is available at www.rhopressa.com . Aerie’s second novel product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil (0.02%) and latanoprost ophthalmic solution (0.005%)), was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain and conjunctival hemorrhage. More information about Rocklatan®, including the product label, is available at www.rocklatan.com . More information on Aerie Pharmaceuticals is available at www.aeriepharma.com . Forward-Looking Statements This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “exploring,” “pursuing” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements in this release include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our commercial franchise and our pipeline, any guidance or timelines, future liquidity, cash balances or financing transactions, our ongoing and anticipated preclinical studies and clinical trials, FDA or other regulatory approvals and effectiveness of any product, product candidates or future product candidates and our expectations for full year 2022. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, industry change and other factors beyond our control and depend on regulatory approvals and economic and other environmental circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We discuss many of these risks in greater detail under the heading “Risk Factors” in the quarterly and annual reports that we file with the Securities and Exchange Commission (SEC). Forward-looking statements are not guarantees of future performance and our actual results of operations, financial condition and liquidity and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. In particular, FDA and European Medicines Agency (EMA) approval of Rhopressa® and Rocklatan® and Medicines and Healthcare products Regulatory Agency (MHRA) authorization of Roclanda® does not guarantee regulatory approval of Rhopressa®, Rocklatan® or Roclanda® in other jurisdictions, and there can be no assurance that we will receive regulatory approval for Rhopressa®, Rocklatan® or Roclanda® in such other jurisdictions. In addition, FDA approval of Rhopressa® and Rocklatan® does not guarantee FDA approval of our product candidates or any future product candidates and there can be no assurance that we will receive FDA approval for our product candidates or any future product candidates. Furthermore, the acceptance of the Investigational New Drug Applications by the FDA for our product candidates does not guarantee FDA approval of such product candidates and the outcomes of later clinical trials for our product candidates may not be sufficient to submit a New Drug Application (NDA) with the FDA or to receive FDA approval. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Non-GAAP Financial Measures To supplement our financial statements, which are prepared and presented in accordance with generally accepted accounting principles (GAAP), we use the following non-GAAP financial measures, some of which are discussed above: adjusted net loss and adjusted net loss per share (also referred to herein as non-GAAP net loss and non-GAAP net loss per share). For reconciliations of non-GAAP measures to the most directly comparable GAAP measures, please see the “Reconciliation of GAAP to Non-GAAP Financial Measures” and “Reconciliation of GAAP Net Loss Per Share to Adjusted Net Loss Per Share (Non-GAAP)” tables in this press release. We believe these non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance and allow for greater transparency with respect to key metrics used by management in operating our business. The presentation of these financial measures is not intended to be considered in isolation from, or as a substitute for, financial information prepared and presented in accordance with GAAP. Investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool. In particular, the adjustments to our GAAP financial measures reflect the exclusion of stock-based compensation expense, which is recurring and will be reflected in our financial results for the foreseeable future. In addition, these measures may be different from non-GAAP financial measures used by other companies, limiting their usefulness for comparison purposes. We compensate for these limitations by providing specific information regarding the GAAP amounts excluded from these non-GAAP financial measures. AERIE PHARMACEUTICALS, INC.

Aerie Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Aerie Pharmaceuticals Rank

  • When was Aerie Pharmaceuticals founded?

    Aerie Pharmaceuticals was founded in 2005.

  • Where is Aerie Pharmaceuticals's headquarters?

    Aerie Pharmaceuticals's headquarters is located at 550 Hills Drive, Bedminster.

  • What is Aerie Pharmaceuticals's latest funding round?

    Aerie Pharmaceuticals's latest funding round is PIPE.

  • How much did Aerie Pharmaceuticals raise?

    Aerie Pharmaceuticals raised a total of $71M.

  • Who are the investors of Aerie Pharmaceuticals?

    Investors of Aerie Pharmaceuticals include Innovate UK and Omidyar Network.

  • Who are Aerie Pharmaceuticals's competitors?

    Competitors of Aerie Pharmaceuticals include Longevica, Noveome Biotherapeutics, VIVUS, Hawaii Biotech, PhaseBio Pharmaceuticals, Hemarina, BioMarck Pharmaceuticals, Aduro BioTech, Potentia Pharmaceuticals, ViroPharma and 17 more.

You May Also Like

A
American Stem Cell

ASC is a privately held biotechnology company dedicated to the development and commercialization of enabling technologies to enhance and expand the therapeutic potential of stem cell therapies. The key technology platforms (ASC-101 and ASC-201) are designed to improve the homing and engraftment of stem cells to target organs and increase their therapeutic potential for cancer patients. Additionally, these platforms have the potential to enhance stem cell treatment of inflammation from chemotherapy/radiation, solid tumors, autoimmune diseases, and ischemic diseases including myocardial infarction and stroke. ASC has strategic partnerships with medical research institutions including the University of Texas M.D. Anderson Cancer Center, the Oklahoma Medical Research Foundation, University of California, the Burnham Institute, Indiana University, Rush Presbyterian and VidaCord Technologia Biomedica.

T
TechnoVax

TechnoVax is a privately held biotechnology company and specializes in vaccine development. The company aims to begin clinical trials within the next 18 months.

N
Nuvelo

Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes alfimeprase, a direct-acting fibrinolytic for the treatment of thrombotic- related disorders including acute ischemic stroke and catheter occlusion and preclinical candidates NU206 for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease and NU172, a direct thrombin inhibitor for use as a short-acting anticoagulant during medical or surgical procedures. In addition, Nuvelo expects to leverage its expertise in cancer antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities.

Hemarina Logo
Hemarina

Hemarina is a privately held biotechnology company focused on the research and development of oxygen-carriers for medical and industrial applications. Hemarina's approach to the development of oxygen transport agents is based on the observation of marine invertebrate colonizing extreme environments and the study of their respiratory adaptations. Hemarina's lead product, Hemarina M-101, is designed to deliver oxygen effectively and efficiently to cells, tissues, organs at risk of oxygen deprivation. Hemarina has already passed a panel of strong proof of concepts obtained during in-vitro and pre-clinical trials.

F
FIBREX Medical

FIBREX Medical Inc. is a development stage bio-pharmaceutical company. Its operational affiliate FIBREX Medical Research & Development GmbH was established in Vienna in February 2001. The company is focused on pharmaceuticals targeting fundamental mechanisms of inflammation and tissue injury. Per FIBREX, while inflammation is highly desirable to defend the organism against foreign particles and infections, it can become harmful and destructive if it runs unchecked. Inflammation-based tissue injury is well known as a major component in the pathogenesis and progression of important diseases such as myocardial infarction, septic and hemorrhagic shock, graft rejection, or rheumatoid arthritis. In addition, endothelial dysfunction in inflamed tissues leads to capillary leak and deleterious edema formation, aggravating organ dysfunction.

ARC Pharmaceuticals Logo
ARC Pharmaceuticals

ARC Pharmaceuticals Inc. is a privately owned biotechnology company developing medical products for the treatment of proliferative diseases. The Company holds exclusive intellectual property related to the treatment of surgical adhesions, rheumatoid arthritis, osteoarthritis and psoriasis. ARC's initial focus is on the prevention of surgical adhesion disease, a major complication in a high proportion of common surgical procedures causing pain and dysfunction in millions of patients worldwide.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.